Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
18 hedge funds and large institutions have $90.6M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2015 Q3 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$22M |
| 2 |
O
OrbiMed
New York
|
+$13.9M |
| 3 |
WT
Wellcome Trust
London,
United Kingdom
|
+$13.1M |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$12.2M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$9.2M |
Top Sellers
NBRV Hedge Fund Activity: Q3 2015 in Review
18 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q3 2015, worth a combined $90.6M.
Buyers outnumbered sellers: 18 funds opened new NBRV positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $22M.
- 18 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q3 2015, up from 0 in Q2 2015.
- Funds reported $90.6M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q3 2015.
- 18 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q3 2015 and 0 closed out, a net change of +18 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q3 2015 was Wellington Management Group, an estimated $22M added.
Based on aggregated 13F filings for Q3 2015.